These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Pneumococcal vaccination]. Léophonte P Rev Mal Respir; 1999 Nov; 16(5):763-6. PubMed ID: 10612144 [No Abstract] [Full Text] [Related]
25. Pneumococcal conjugate vaccine for young children. Zimmerman RK Am Fam Physician; 2001 May; 63(10):1991-8. PubMed ID: 11388715 [TBL] [Abstract][Full Text] [Related]
26. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Hausdorff WP; Bryant J; Paradiso PR; Siber GR Clin Infect Dis; 2000 Jan; 30(1):100-21. PubMed ID: 10619740 [TBL] [Abstract][Full Text] [Related]
27. Use of the new pneumococcal conjugate vaccine in the USA. Baucher H Arch Dis Child; 2000 Nov; 83(5):396. PubMed ID: 11040145 [No Abstract] [Full Text] [Related]
28. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease. Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319 [TBL] [Abstract][Full Text] [Related]
29. Conjugate pneumococcal vaccine and antibiotic-resistant Streptococcus pneumoniae: herd immunity and reduction of otitis morbidity. Dagan R; Fraser D Pediatr Infect Dis J; 2000 May; 19(5 Suppl):S79-87; discussion S88. PubMed ID: 10821476 [No Abstract] [Full Text] [Related]
33. Clinical trial of the protective role of polyvalent pneumococcal vaccine in sickle cell anaemia patients in Zambia. Chintu C; Gupta K; Osborne C; Masona JM Med J Zambia; 1983 Jul; 17(3):73-6. PubMed ID: 6679155 [No Abstract] [Full Text] [Related]
34. Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Givon-Lavi N; Fraser D; Dagan R Pediatr Infect Dis J; 2003 Jun; 22(6):524-32. PubMed ID: 12799509 [TBL] [Abstract][Full Text] [Related]
36. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Hausdorff WP; Bryant J; Kloek C; Paradiso PR; Siber GR Clin Infect Dis; 2000 Jan; 30(1):122-40. PubMed ID: 10619741 [TBL] [Abstract][Full Text] [Related]
37. Immune responses to polysaccharides: lessons from humans and mice. González-Fernández A; Faro J; Fernández C Vaccine; 2008 Jan; 26(3):292-300. PubMed ID: 18160186 [TBL] [Abstract][Full Text] [Related]
38. Acute otitis media caused by antibiotic-resistant Streptococcus pneumoniae in southern Israel: implication for immunizing with conjugate vaccines. Dagan R; Givon-Lavi N; Shkolnik L; Yagupsky P; Fraser D J Infect Dis; 2000 Apr; 181(4):1322-9. PubMed ID: 10753730 [TBL] [Abstract][Full Text] [Related]
39. Pneumococcal conjugate vaccine. What you need to know. S D Med; 2006 Dec; 59(12):528-9. PubMed ID: 17212186 [No Abstract] [Full Text] [Related]
40. Prevnar (heptavalent pneumococcal conjugate vaccine): disease prevention in infants and children. Shields B J Pediatr Health Care; 2001; 15(4):203-8; quiz 209-10. PubMed ID: 11462129 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]